Loading...
Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia
Rituximab (RTX), an antibody targeting CD20, is widely used as a first-line therapeutic strategy in B cell–mediated autoimmune diseases. However, a large proportion of patients either do not respond to the treatment or relapse during B cell reconstitution. Here, we characterize the cellular basis re...
Na minha lista:
| Udgivet i: | Sci Transl Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7610758/ https://ncbi.nlm.nih.gov/pubmed/33853929 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.abc3961 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|